# A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma

> **NCT00359294** · PHASE1 · TERMINATED · sponsor: **PharmaMar** · enrollment: 12 (actual)

## Conditions studied

- Solid Tumors
- Lymphoma

## Interventions

- **DRUG:** PM00104

## Key facts

- **NCT ID:** NCT00359294
- **Lead sponsor:** PharmaMar
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Low recruitment
- **Last updated:** 2021-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00359294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00359294, "A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00359294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*